* Newstin.com is for sale! * After achieving our strategic milestone, we are offering for sale: Newstin.com and all 14 related domains featuring 1 million unique visitors per month + continuously updated news database of 37 million articles in 12 world languages from 166,000 global and weighted sources + 2.1 billion metadata * To seize this unique chance, contact invest@newstin.com. * Newstin.com is for sale! *

GPC Biotech

                   

Eli Lilly's Dose of Disclosure (at Motley Fool)

yahoo.com
Sep 25, 2008 25 related
        

The Fool has long stood for more disclosure and transparency for publicly traded companies. Earlier this week, pharma giant Eli Lilly (NYSE: LLY) announced that in the coming year, it would begin disclosing the fees it...

add comment
                   
genengnews.com: Genetic Engineering genengnews.com

Gerhard Muller to Lead Proteros' Fragment Based Service Offering

genengnews.com
Aug 18, 2008
        

News source: Business Wire Proteros biostructures today announced that Dr. Gerhard Muller has joined the management team to lead the company's service initiative in fragment based lead generation. Gerhard joins the Proteros...

add comment
                   
genengnews.com: Genetic Engineering genengnews.com

GPC Biotech Reports Financial Results for Second Quarter and First Six Months of 2008 (Business...

yahoo.com
Aug 13, 2008 5 related
        

Wednesday August 13, 1:35 am ET -- Company confirms that existing cash position expected to support currently planned business operations until approximately the end of 2010 MARTINSRIED, Germany & MUNICH, Germany & PRINCETON,...

add comment
                   

Celgene Calls it Quits in GPC Satraplatin Deal

tmcnet.com
Aug 7, 2008 3 related
        

Celgene Corp. has ended its nearly three-year partnership with embattled German firm GPC Biotech AG on its prostate cancer drug satraplatin. European regulators said the drug's application, submitted in June 2007, was not...

add comment

GPC Biotech to withdraw marketing application for satraplatin

pharmaceutical-business-review.com
Jul 29, 2008 3 related
        

GPC Biotech has reported that the company has been informed by its partner for satraplatin in Europe that they plan to withdraw the marketing authorization application for satraplatin plus prednisone for the treatment of...

add comment

Analyst Actions: Amgen, American Axle

orglex.com
Jul 28, 2008 1 related
        

A sedative Eisai gained through its acquisition of MGI Pharma has been hit with a ‘not approvable' letter from the FDA. But the pharma company says it strongly believes that further talks with the agency will lead to an...

add comment

GPC partners pull cancer drug application

ibtimes.com
Jul 25, 2008 12 related
        

NEW YORK - German biotechnology company GPC Biotech AG said Friday its European partner withdrew an application for the troubled cancer drug candidate satraplatin, a move made by GPC in the U.S. last year. "Although we...

add comment
                   

GPC Biotech To Re-Schedule Annual Shareholders' Meeting (Business Wire)

yahoo.com
Jul 17, 2008 5 related
        

MARTINSRIED/MUNICH, Germany & PRINCETON, N.J.----GPC Biotech AG today announced that the Company has re-scheduled its Annual Shareholders' Meeting to December 16, 2008 in Munich. The meeting was previously scheduled for August...

add comment
                   

GPC Biotech To Re-Schedule Annual Shareholders' Meeting

finanznachrichten.de
Jul 17, 2008 2 related
        

GPC Biotech AG (Frankfurt Stock Exchange: GPC, NASDAQ: GPCB) today announced that the Company has re-scheduled its Annual Shareholders' Meeting to December 16, 2008 in Munich. The meeting was previously scheduled for August 27,...

add comment

GPC Biotech Kicks Off Phase II Trial for Prostate Cancer Drug

pharmiweb.co.uk
Jul 1, 2008 7 related
        

GPC Biotech is beginning a clinical trial testing satraplatin combined with the steroid prednisone in patients with metastatic hormone-refractory prostate cancer who have been treated with docetaxel, a chemotherapy drug....

add comment
1 2 3 4 5 next »